AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

This trial is testing AK112 — a drug that simultaneously blocks both PD-1 (an immune checkpoint) and VEGF (a protein that helps tumors grow blood vessels) — combined with nab-paclitaxel chemotherapy as a first-line treatment for triple-negative breast cancer that cannot be surgically removed or has spread. **You may be eligible if...** - You have been diagnosed with unresectable locally advanced or metastatic triple-negative breast cancer (ER-negative, PR-negative, and HER2-negative) - You have not previously received systemic treatment for advanced breast cancer - You are between 18 and 75 years old - Your general health is good (ECOG score 0 or 1) - You have at least one measurable tumor lesion - You are suitable for taxane-based single-agent chemotherapy **You may NOT be eligible if...** - You have received prior chemotherapy for advanced disease - Your cancer is locally recurrent and can still be surgically removed or treated with radiation - You have serious organ dysfunction or active infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.